These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37119921)

  • 1. Calculated Globulin as a potential screening tool for paraproteinemia to aid in the early diagnosis of Multiple Myeloma.
    O'Brien A; Bransfield A; O'Halloran F; Mykytiv V
    Clin Biochem; 2023 Jun; 116():113-119. PubMed ID: 37119921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculated Globulin Is Clinically Useful as a Screening Test for Antibody Deficiency in Turkish Adult Patients.
    Yegit OO; Karadağ P; Eyice D; Oztop N; Beyaz Ş; Tüzer ÖC; Can A; Demir S; Erdoğdu D; İşsever H; Genç S; Ömer B; Jolles S; Gelincik Akkor A
    Int Arch Allergy Immunol; 2023; 184(8):822-831. PubMed ID: 37166344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients.
    Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C
    Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital.
    Pecoraro A; Jolles S; Crescenzi L; Varricchi G; Marone G; Savoia M; Genovese A; Spadaro G
    Curr Pharm Biotechnol; 2018; 19(9):728-733. PubMed ID: 30091407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma.
    Ong F; Hermans J; Noordijk EM; De Kieviet W; Seelen PJ; Wijermans PW; Kluin-Nelemans JC
    Leuk Lymphoma; 1997 Nov; 27(5-6):495-501. PubMed ID: 9477131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the albumin-globulin ratio and albumin-globulin score in patients with multiple myeloma.
    Cai Y; Zhao Y; Dai Q; Xu M; Xu X; Xia W
    J Int Med Res; 2021 Mar; 49(3):300060521997736. PubMed ID: 33682516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of unknown significance and malignant paraproteinemia in Hong Kong.
    Lolin YI; Chow J; Wickham NW
    Am J Clin Pathol; 1996 Oct; 106(4):449-56. PubMed ID: 8853031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
    Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
    Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 11. Biochemical profile of Bence-Jones type multiple myeloma.
    Lyubimova NV; Timofeev YS; Abaev VM; Votyakova OM; Osmanov EA; Kushlinskii NE
    Klin Lab Diagn; 2022 Oct; 67(10):570-574. PubMed ID: 36315171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia.
    Berger T; Shacham Abulafia A; Shimony S; Pasvolsky O; Vaxman I; Miron Y; Feldman S; Leader A; Raanani P
    Acta Haematol; 2022; 145(6):619-626. PubMed ID: 35908535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of
    Hill E; Mena E; Morrison C; Dew A; Choyke P; Lindenberg L; Kazandjian D
    Br J Haematol; 2021 Apr; 193(1):125-128. PubMed ID: 32966607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
    Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS
    Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 16. [The CBO professional guideline 'monoclonal gammopathy' (paraproteinemia) (revision)].
    Buiting AM; Wijermans PW
    Ned Tijdschr Geneeskd; 2002 Jul; 146(30):1406-11. PubMed ID: 12174434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis.
    Goldschmidt N; Zamir L; Poperno A; Kahan NR; Paltiel O
    J Am Board Fam Med; 2016 Nov; 29(6):702-709. PubMed ID: 28076253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity.
    Kousios A; Duncan N; Charif R; Roufosse C
    J Am Soc Nephrol; 2018 Dec; 29(12):2901. PubMed ID: 30377233
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.